TCGA-UF-A719-01A-12R-A34R-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.420
- E2F_TARGETS+0.350
- G2M_CHECKPOINT+0.320
- KRAS_SIGNALING_DN+0.200
- MITOTIC_SPINDLE+0.190
- CHOLESTEROL_HOMEOSTASIS+0.160
- INTERFERON_GAMMA_RESPONSE+0.150
- SPERMATOGENESIS+0.150
- FATTY_ACID_METABOLISM+0.130
- BILE_ACID_METABOLISM+0.110
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.560
- ANGIOGENESIS-0.470
- TGF_BETA_SIGNALING-0.430
- HYPOXIA-0.380
- PROTEIN_SECRETION-0.350
- UV_RESPONSE_DN-0.350
- ALLOGRAFT_REJECTION-0.330
- PANCREAS_BETA_CELLS-0.330
- IL2_STAT5_SIGNALING-0.320
- PI3K_AKT_MTOR_SIGNALING-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR2932834 | — | — | 0.812 |
| 2 | SRR8518445 | — | C | 0.808 |
| 3 | R68 | — | — | 0.807 |
| 4 | SRR12202474 | — | — | 0.787 |
| 5 | C3N-04162 | — | cohortSQ2 | 0.778 |
| 6 | TCGA-RS-A6TP-01A-12R-A34R-07 | — | — | 0.766 |
| 7 | TCGA-CN-A49C-01A-11R-A24H-07 | — | — | 0.766 |
| 8 | R93 | — | — | 0.758 |
| 9 | SRR8518168 | — | E | 0.754 |
| 10 | 2d8478f6-41ac-47f5-ac3c-337af7245f5b | — | — | 0.753 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.420 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.350 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.320 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.190 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.160 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.150 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.150 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.130 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.110 | Inavolisib | — uncovered |
| APOPTOSIS | 0.070 | Idelalisib | — uncovered |
| PEROXISOME | 0.070 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.070 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.050 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.050 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.040 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.040 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.020 | Idelalisib | — uncovered |